IDH3A and glioblastoma: It has been used to grade tumours, evaluate response to therapy and predict genetic status of GBM—for example, isocitrate dehydrogenase (IDH) status in GBM, which is of clinical significance since negative status (or ‘wildtype’) implies a more aggressive tumour [33].